Crossmark

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways

Crossref DOI link: https://doi.org/10.1007/s40263-018-0601-x

Published Online: 2019-01-28

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Green, Holly

Tsitsi, Panagiota

Markaki, Ioanna

Aarsland, Dag

Svenningsson, Per https://orcid.org/0000-0001-6727-3802
Funding

Funding for this research was provided by:

Stockholms Läns Landsting (20160372)

Knut och Alice Wallenbergs Stiftelse (WCS 2016)

Kings College London (2018)
License Information

Text and Data Mining valid from 2019-01-28
More Information

Article History

First Online: 28 January 2019

Compliance with Ethical Standards

:

: PS and PT are co-investigators on MOVES-PD and have been co-investigators in a clinical trial with IRL75 against dementia in Parkinson’s disease. PS has also received grants from Servier and honoraria from IRLAB, AbbVie and Shire. DA has received research support and/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health, and serves as a paid consultant for H. Lundbeck, Eisai and Heptares. HG and IM have no conflicts of interest directly relevant to the content of this article.

: The work was supported by the Stockholm County Council (Grant number 20160372) and King’s College London. Per Svenningsson is a Wallenberg Clinical Scholar. Dag Aarsland is a Royal Society Wolfson Research Merit Award Holder and would like to thank the Wolfson Foundation for their support. The open access fee was paid by Professor Svenningson's funding from the Karolinska Institutet.